Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On November 12, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the third quarter of 2025 and provided a business update.</li><li>The first patient to be treated with Zevaskyn was moved to the fourth quarter of 2025 following the optimization of a product release assay.</li><li>Interest continues to build for Zevaskyn, with the company having received Zevaskyn product order forms (ZPOFs) for 12 patients, all of which are in the process of scheduling treatments.</li></ul>

On November 12, 2025, Abeona Therapeutics, Inc. (ABEO) announced financial results for the third quarter of 2025 and provided a business update.The first patient to be treated with Zevaskyn was moved to the fourth quarter of 2025 following the optimization of a product release assay.Interest continues to build for Zevaskyn, with the company having received Zevaskyn product order forms (ZPOFs) for 12 patients, all of which are in the process of scheduling treatments.

ABEO: First Patient Treated with Zevaskyn  Pushed to 4Q25 Following Assay Optimization